Global Fucosidosis Treatment Market - 2023-2030

Global Fucosidosis Treatment Market - 2023-2030

The global fucosidosis treatment market reached US$ XX billion in 2022 and is expected to reach US$ XX billion by 2030 growing with a CAGR of XX% during the forecast period 2023-2030.

The fucosidosis treatment market trends show rising research owing to the rising technological advancements and research studies. Several therapies are being researched for the treatment of fucosidosis. Bone marrow transplant can also be utilized for the management of fucosidosis.

Furthermore, rising pipeline for fucosidosis treatment due to the rising research and development of therapies with positive outcomes and increase in the number of fucosidosis treatment cases in the market, and an increase in the research and development is driving up the fucosidosis treatment market size.

The market is experiencing a growth in demand for treatment from North American areas as a result of the rising advancements in this field. With significant competitors like Merck KGaA, JCR Pharmaceuticals Co., Ltd., Orchard Therapeutics plc, and Merck KGaA actively operating in the market, the market will grow in upcoming time.

Dynamics

Growing Research and Development by the Researchers Drive the Growth of the Fucosidosis Treatment Market

Numerous research and developments are currently taking place by the researchers for finding treatment of fucosidosis alysosomal disease. In canines with fucosidase deficiency, hematopoietic stem cell transplantation (HSCT) exhibited promising results; -L-fucosidase enzyme activity regulated in plasma, leucocytes, and brain and visceral organs.

A small number of individuals with fucosidosis had HSCT, and in some cases, the symptoms stabilized. The procedure was initially tried on an asymptomatic 7-month-old infant who was identified as having fucosidosis following the identification of the symptomatic elder sibling. When it was discovered to be a successful treatment, it was applied sparingly and only on carefully chosen patients.

In fucosidosis, earlier transplant proved to be more successful than transplant following symptoms have fully developed. Following a successful transplant, -L fucosidase levels in white blood cells, plasma, and cerebrospinal fluid gradually increased, and an MRI scan showed improved myelination. Such kind of researches with positive outcomes will result in high growth of the market in coming years.

Rising Robust Pipeline and Technological Advancements Create a Lucrative Opportunities for Growth of the Market

Currently several major players are developing novel therapies for the treatment of fucosidosis, the products are in the pipeline. These companies are developing strategic initiatives such as partnerships, research and development, collaborations or robust pipeline for increasing the growth of the market.

JCR Pharmaceuticals Co., Ltd. announced its choice to utilize J-Brain Cargo, JCR's patented BBB penetrating technology, to the development of a JR-471, a novel therapeutic candidate, blood-brain barrier (BBB)-penetrating -L-fucosidase for the treatment of patients with fucosidosis. Fucosidosis is a type of lysosomal storage disorder which is inherited in an autosomal recessive way and is the new target indication.

Glycans and glycoproteins build up throughout the body as a result of a glycoprotein-metabolizing enzyme (-fucosidase) malfunctioning due to mutations. The intravenously injected JR-471 showed brain delivery and a decrease in the disease-causing components in the brain in preliminary research conducted by JCR utilizing disease-model mice. These kind of factors are responsible for developing opportunities for the growth of the market.

Complications Associated with Hematopoietic Stem Cell Therapy will Hamper the Growth of the Market

Following a bone marrow transplant, complications might be sudden or gradual. The source of the stem cell transplant, age, baseline performance condition, type of preparative regimen, and intensity can all have an impact on these adverse effects. Chronic side effects include varicella-zoster virus reactivation, encapsulated bacterial infection, and chronic GVHD.

Myelosuppression with anemia, neutropenia, or thrombocytopenia, mucositis, sinusoidal obstruction syndrome, acute graft versus host disease, gram-positive or gram-negative bacterial infections, herpesviridae infections, as well as fungal infections with Aspergillus or Candida are just a few of the acute complications that can happen within the first 90 days.

Segment Analysis

The global fucosidosis treatment market is segmented based on type, treatment and end user.

Owing to High Incidence, the Fucosidosis Type II from Type Segment Accounted for Approximately 62% of the Fucosidosis Treatment Market Share

The fucosidosis type II category from type held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a more number of cases of fucosidosis worldwide. Type II is linked to a longer survival time, angiokeratoma corporis diffusum development, and milder psychomotor decline and neurologic symptoms.

Fucosidosis type II sufferers may have coarsened facial features, developmental delays, speech and/or language impairments, hypotonia, slow development, hepatosplenomegaly, vertebral defects, cardiomegaly, minor retinal vascular alterations, epileptic attacks, angiokeratomas, telangiectasias, defects in central regulation of body temperature, and a slowly progressing neurodegenerative condition with a developing encephalopathy, the upper motor neuron dysfunction with hyperreflexia.

Delay in bone age, spondyloepiphyseal dysplasia, dysostosis multiplex, hip dysplasia, as well as diaphyseal expansion of long bones are further abnormalities. Hypomyelination may be detected by brain MRI. White matter in the cerebellum, periventricular region of the brain, lobar region, and subcortical region can be seen on T2-weighted imaging as areas of signal hyperintensity. These all abnormalities are associated with type II fucosidosis.

Geographical Penetration

North America Accounted for Approximately 34.2% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for fucosidosis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for fucosidosis treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of lysosomal diseases, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of fucosidosis treatment market share of this region.

The key healthcare organizations' and businesses' joint research initiatives are also expected to contribute to the rising demand, as will new product development, which constantly looks to improve present options. The market in this area is growing as people become more aware of various treatments, such as bone marrow transplants, for management purposes. The aforementioned elements further attest to North America's hegemonic position in the world.

Competitive Landscape
The major global players in the fucosidosis treatment market include Merck KGaA, JCR Pharmaceuticals Co., Ltd., Orchard Therapeutics plc, Protalix BioTherapeutics, Inc., Magenta Therapeutics, Evotec SE, Jasper Therapeutics, Inc., Hemogenyx Pharmaceuticals plc, Garuda Therapeutics and STEMPEUTICS RESEARCH PVT LTD. among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide fucosidosis treatment market. The growth of the global fucosidosis treatment market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Type
• Fucosidosis Type I
• Fucosidosis Type II

By Treatment
• Antibiotic Therapy
• Fluid Replacement Therapy
• Hematopoietic-Stem-Cell Transplantation
• Enzyme Replacement Therapy

By End User
• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On October 31, 2023, a memorandum of understanding on the granting of special negotiation rights for the global marketing outside of Japan of four fresh drug candidates being produced for ultra-rare lysosomal storage diseases (LSDs) by JCR was executed, Their boards of directors resolved, according to an announcement from JCR Pharmaceuticals Co., Ltd and MEDIPAL HOLDINGS CORPORATION. Additionally, the two businesses have reached an agreement to license for a therapeutic candidate for the management of fucosidosis in line with the execution of the memorandum.
• On February 7, 2023, Garuda Therapeutics disclosed a $62 million Series B funding led by Northpond Ventures, Cormorant Asset Management, OrbiMed Advisors, and Aisling Capital, with involvement from Mass General Brigham Ventures, Sectoral Asset Management, Alexandria Venture Investments, along with other prestigious investors and individuals. The company develops off-the-shelf, robust cellular therapies based on blood stem cell. The company has received $134 million in investment in all.

DMI Opinion:

The global fucosidosis treatment market is going to see moderate growth in upcoming years owing to rising usage of enzyme replacement therapy for fucosidosis treatment. Several researches are taking place worldwide for stem cell transplant therapy development. Numerous advances are taking place leading to the growth of market such as fluid replacement therapy. According to DMI the fucosidosis treatment market will see a decent growth with several novel therapies in the market.

Why Purchase the Report?
• To visualize the global fucosidosis treatment market segmentation based on type, treatment, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of fucosidosis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global fucosidosis treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies Show more